Zydus Cadila will start manufacturing anti-cholesterol tablet Ezetimibe from its plant in Moraiya, Ahmedabad, after getting approval from US Food and Drug Administration (US FDA) to market the drug in that country, the pharma major said on Tuesday.
Ezetimibe registered an annual sales of approximately $2.7 billion in the US till April 2017, according to global pharmaceutical market research firm IMS Health.
Zydus and Sun Pharmaceutical have received US FDA approval to market Ezetimibe in the US, underscoring the demand for affordable anti-cholesterol drugs in the market.
The Centre for Disease Control and Prevention data shows that 73.5 million adults (31.7 per cent) in the US have high low-density lipoprotein (LDL), or “bad,” cholesterol. People with high total cholesterol have approximately twice the risk for heart disease as people with ideal levels.
Top Indian pharma companies are focusing to the serve the US market with affordable generics in view of the growing incidences of life-style diseases and high cost of healthcare in the country.